Please assess the completion status of the following clinical trial:

Trial Title: Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women, aged 20-45, with regular menses and no historical or biochemical secondary cause of osteoporosis.~* Documented adult fractures judged to be low-trauma.~* Must be willing to use effective contraception throughout the period of study drug administration.~Inclusion Criteria - vary slightly based on age category:~* Premenopausal women ages 20-35 years must have at least one major osteoporotic fracture (excluding fractures of fingers, toes and face) and low Bone Mineral Density (BMD).~* Premenopausal women above the age of 35 years should have a history of fracture and/or low BMD.~Exclusion Criteria:~* History of any condition that increases the risk of osteosarcoma~* Early follicular phase serum~* Disorders of mineral metabolism~* Suspicion of osteomalacia~* Vitamin D deficiency~* Pregnancy or lactation within past 12 months~* Prolonged amenorrhea (\> 6 months) during reproductive years (except pregnancy or lactation)~* Prior eating disorder~* Malignancy, except cured basal or squamous cell skin carcinoma~* Endocrinopathy: new onset untreated hyperthyroidism, hypothyroidism, Cushing's syndrome, prolactinoma~* Renal insufficiency~* Liver disease~* Intestinal disorders~* History/current glucocorticoids (GCs), anticonvulsants, anticoagulants, methotrexate, depot progesterone, Gonadotrophin-releasing hormone (GnRH) agonists~* Oral glucocorticoid use (subject will not be excluded if used dose equivalent to less than prednisone 5 mg for \<3 months).~* Current anticoagulant use or low molecular weight~* Depo Provera use (subjects will not be excluded if used at age\>20, \>5 years ago)~* Drugs for osteoporosis (raloxifene, bisphosphonates, denosumab, calcitonin, TPTD). Subjects who discontinue these medications will be eligible 3 months after stopping raloxifene or calcitonin, 12 months after stopping alendronate, risedronate, ibandronate, or pamidronate and 18 months after stopping denosumab. Subjects with prior use of zoledronate may be eligible if received only one dose \>4 years ago. Total bisphosphonate exposure must be \< 1 year. Subjects who have taken TPTD in the past will not be eligible unless used for \<3 months, \> 2 years ago.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Forteo) (Type: ACTIVE_COMPARATOR): Daily injection of Teriparatide for treatment of idiopathic osteoporosis
- Placebo saline injection (Type: PLACEBO_COMPARATOR): Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).